4.7 Article

Combination of the Framingham Risk Score and Carotid Intima-Media Thickness Improves the Prediction of Cardiovascular Events in Patients With Type 2 Diabetes

期刊

DIABETES CARE
卷 35, 期 1, 页码 178-180

出版社

AMER DIABETES ASSOC
DOI: 10.2337/dc11-1333

关键词

-

向作者/读者索取更多资源

OBJECTIVE The aim of this study was to investigate whether carotid intima-media thickness (IMT) and brachial-ankle pulse wave velocity (baPWV) add value to the Framingham risk score (FRS) in predicting the development of cardiovascular diseases (CVDs) in type 2 diabetic patients with a negative history of CVD. RESEARCH DESIGN AND METHODS Type 2 diabetic patients (n = 783) were retrospectively recruited and followed for CVD. RESULTS During a 5.4-year follow-up period, 85 incidences of CVD were recorded (10.9%). After adjustment for conventional arterial risk factors, multivariate analysis with the Cox proportional hazards model identified IMT, but not baPWV, as a significant determinant of CVD. In addition, the combination of FRS with IMT, but not with baPWV, improved the prediction of CVD. CONCLUSIONS Carotid IMT is a significant predictor of CVD in asymptomatic type 2 diabetic patients, and the combination of FRS and IMT improves the prediction of CVD in these patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Editorial Material Endocrinology & Metabolism

Inceptor intercepts insulin signaling in pancreatic β-cells

Hirotaka Watada

JOURNAL OF DIABETES INVESTIGATION (2021)

Article Endocrinology & Metabolism

Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials

Eiichi Araki, Yasuo Terauchi, Hirotaka Watada, Srikanth Deenadayalan, Erik Christiansen, Hiroshi Horio, Takashi Kadowaki

Summary: The study aimed to evaluate the efficacy and safety of oral semaglutide compared to other drugs in Japanese patients with type 2 diabetes. The results showed that oral semaglutide effectively lowered HbA1c levels and body weight in Japanese patients, with gastrointestinal adverse events being the most common. Overall, oral semaglutide was well tolerated and showed promising results in Japanese patients.

DIABETES OBESITY & METABOLISM (2021)

Article Biochemistry & Molecular Biology

Short-Term SGLT2 Inhibitor Administration Does Not Alter Systemic Insulin Clearance in Type 2 Diabetes

Motonori Sato, Yoshifumi Tamura, Hideyoshi Kaga, Nozomu Yamasaki, Mai Kiya, Satoshi Kadowaki, Daisuke Sugimoto, Takashi Funayama, Yuki Someya, Saori Kakehi, Shuko Nojiri, Hiroaki Satoh, Ryuzo Kawamori, Hirotaka Watada

Summary: The study showed that SGLT2i tofogliflozin did not affect the metabolic clearance rate of insulin, but could improve glycated hemoglobin levels and reduce body weight.

BIOMEDICINES (2021)

Article Endocrinology & Metabolism

Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period

Caroline Reilhac, Julie Dubourg, Carole Thang, Jean-Marie Grouin, Pascale Fouqueray, Hirotaka Watada

Summary: This study evaluated the efficacy and safety of imeglimin as combination therapy with insulin in Japanese patients with type 2 diabetes. The results showed that imeglimin significantly improved HbA1c levels and had a similar safety profile to placebo.

DIABETES OBESITY & METABOLISM (2022)

Article Endocrinology & Metabolism

Spatial and transcriptional heterogeneity of pancreatic beta cell neogenesis revealed by a time-resolved reporter system

Shugo Sasaki, Michelle Y. Y. Lee, Yuka Wakabayashi, Luka Suzuki, Helena Winata, Miwa Himuro, Taka-aki Matsuoka, Iichiro Shimomura, Hirotaka Watada, Francis C. Lynn, Takeshi Miyatsuka

Summary: This study investigates the characteristics of newborn beta cells and their transcriptomic profiles using a time-resolved reporter system. The findings reveal spatial and transcriptional heterogeneity in beta cell neogenesis, providing insights into beta cell differentiation and future cell therapy.

DIABETOLOGIA (2022)

Article Cell & Tissue Engineering

Phase I/IIa Feasibility Trial of Autologous Quality- and quantity-Cultured Peripheral Blood Mononuclear Cell Therapy for Non-Healing Extremity Ulcers

Rica Tanaka, Satoshi Fujimura, Makiko Kado, Taro Fukuta, Kayo Arita, Rie Hirano-Ito, Tomoya Mita, Hirotaka Watada, Yoshiteru Kato, Katsumi Miyauchi, Hiroshi Mizuno

Summary: MNC-QQ therapy shows promising efficacy in chronic non-healing ischemic extremity wounds, improving vascular and skin perfusion and reducing pain intensity. It is also safe for patients.

STEM CELLS TRANSLATIONAL MEDICINE (2022)

Article Medicine, General & Internal

Identification of Risk Factors for Coronary Artery Disease in Asymptomatic Patients with Type 2 Diabetes Mellitus

Kazuhisa Takamura, Shinichiro Fujimoto, Tomoya Mita, Yuko Okano Kawaguchi, Mika Kurita, Satoshi Kadowaki, Yuki Kamo, Chihiro Aoshima, Yui Okada Nozaki, Daigo Takahashi, Ayako Kudo, Makoto Hiki, Nobuo Tomizawa, Fuki Ikeda, Hiroaki Satoh, Hirotaka Watada, Tohru Minamino

Summary: Among asymptomatic patients with type 2 diabetes, current smoking, Agatston score >= 100, and insulin treatment are independent predictive factors for high-risk coronary artery disease (CAD) patients. Non-invasive examinations, except for the Agatston score, are not independent predictors of high-risk CAD patients.

JOURNAL OF CLINICAL MEDICINE (2022)

Review Endocrinology & Metabolism

Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan

Takashi Kadowaki, Hiroshi Maegawa, Hirotaka Watada, Daisuke Yabe, Koichi Node, Toyoaki Murohara, Jun Wada

Summary: There is a interaction between metabolic disorders, cardiovascular disease, and kidney dysfunction, known as cardio-renal-metabolic (CRM) disease. Understanding the molecular mechanisms and pathophysiological processes of CRM disease is crucial for improving patient outcomes, and there may be differences in CRM diseases between different regions.

DIABETES OBESITY & METABOLISM (2022)

Article Transplantation

Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study

Masanomi Nangaku, Hirotaka Takama, Tomohiro Ichikawa, Kazuya Mukai, Masahiro Kojima, Yusuke Suzuki, Hirotaka Watada, Takashi Wada, Kohjiro Ueki, Ichiei Narita, Naoki Kashihara, Takashi Kadowaki, Hiroki Hase, Tadao Akizawa

Summary: This study aims to evaluate the efficacy and safety of bardoxolone methyl in diabetic kidney disease (DKD) patients with reduced estimated glomerular filtration rate (eGFR) and elevated urinary albumin:creatinine ratio (UACR). Results show that patients enrolled in the study meet the criteria, and the study will investigate the long-term efficacy and safety of bardoxolone methyl in this patient population.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Article Endocrinology & Metabolism

A 7 day inpatient diabetes education program improves quality of life and glycemic control 12 months after discharge

Mika Kurita, Hiroaki Satoh, Hideyoshi Kaga, Satoshi Kadowaki, Yuki Someya, Yuka Tosaka, Yuya Nishida, Fuki Ikeda, Yoshifumi Tamura, Hirotaka Watada

Summary: To achieve long-term management of diabetes, patients with type 2 diabetes mellitus need high treatment adherence, which is associated with treatment satisfaction and quality of life. Patient education about diabetes self-management is essential. This study investigates the improvement of quality of life and post-discharge glycemic control in patients with type 2 diabetes mellitus through a diabetes education program.

JOURNAL OF DIABETES INVESTIGATION (2023)

Article Endocrinology & Metabolism

Effect of patient characteristics on the efficacy and safety of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of two randomized, placebo-controlled trials

Katsuhiko Hagi, Kenji Kochi, Hirotaka Watada, Kohei Kaku, Kohjiro Ueki

Summary: This study analyzed the efficacy and safety of imeglimin 1,000 mg twice daily monotherapy in type 2 diabetes mellitus patients, considering their demographic and clinical characteristics. The results showed statistically significant differences in HbA1c levels between imeglimin and placebo across all patient subgroups analyzed. The efficacy and safety of imeglimin were confirmed across a broad spectrum of patients with type 2 diabetes mellitus, with no new safety concerns identified in any patient subpopulations.

JOURNAL OF DIABETES INVESTIGATION (2023)

Article Neurosciences

Reduced gray matter volume in the default-mode network associated with insulin resistance

Saki Asano, Akitoshi Ogawa, Takahiro Osada, Satoshi Oka, Koji Nakajima, Yasushi Oshima, Sakae Tanaka, Hideyoshi Kaga, Yoshifumi Tamura, Hirotaka Watada, Ryuzo Kawamori, Seiki Konishi

Summary: Insulin resistance may lead to structural and functional abnormalities in the human brain, which may be mediated through resting-state functional connectivity between the hypothalamus and the cerebral cortex.

CEREBRAL CORTEX (2023)

Article Endocrinology & Metabolism

Efficacy, safety and tolerability of imeglimin in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials

Katsuhiko Hagi, Masahiro Nitta, Hirotaka Watada, Kohei Kaku, Kohjiro Ueki

Summary: This meta-analysis evaluated the efficacy and safety of imeglimin in monotherapy and adjunctive therapy for patients with type 2 diabetes mellitus. The results showed that imeglimin significantly reduced glycated hemoglobin levels as both monotherapy and adjunctive therapy, and it was well tolerated and safe.

JOURNAL OF DIABETES INVESTIGATION (2023)

Article Endocrinology & Metabolism

Diabetic ketoacidosis due to a sensor defect of FreeStyle Libre: A case report

Toshiki Kogai, Junko Sato, Marin Hirakata, Tatsuya Iwamoto, Kenichi Nakajima, Hiromasa Goto, Yuya Nishida, Hirotaka Watada

Summary: The FreeStyle Libre Flash Glucose Monitoring System can provide sensor glucose values through scanning. However, this case report highlights the importance of considering sensor defects as they can lead to severe complications like diabetic ketoacidosis. Even though the device showed lower glucose values, the patient mistook it for hypoglycemia and reduced insulin dosage, ultimately leading to diabetic ketoacidosis. It is crucial to remind patients about the potential risk of sensor defects despite the benefits of glucose monitoring with this system.

JOURNAL OF DIABETES INVESTIGATION (2023)

Article Endocrinology & Metabolism

ALDH2 rs671 Is Associated With Elevated FPG, Reduced Glucose Clearance and Hepatic Insulin Resistance in Japanese Men

Kageumi Takeno, Yoshifumi Tamura, Saori Kakehi, Hideyoshi Kaga, Ryuzo Kawamori, Hirotaka Watada

Summary: The study found that individuals carrying the ALDH2 rs671 G/G genotype had higher alcohol consumption, elevated fasting plasma glucose, lower hepatic insulin sensitivity, and reduced fasting glucose clearance compared to those carrying the non-risk alleles. These results suggest that high alcohol intake may lead to hepatic insulin resistance and reduced fasting glucose clearance in carriers of the ALDH2 rs671 G/G genotype.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

暂无数据